60252-4

MGMT gene methylation [Presence] in Tissue by Molecular genetics method

Active

Part Descriptions

LP101173-5   MGMT gene methylation
O(6)-methylguanine-DNA methyltransferase (MGMT) is an essential enzyme involved in the repair of damage caused by a variety of DNA crosslinking compounds, including alkylating agents. Hypermethylation of the MGMT gene promoter region causes diminished or silenced expression of the gene, making cells more sensitive to DNA damage and prone to tumor development. Approximately 40% to 45% of glioblastoma multiforme (GBM) tumors exhibit MGMT gene methylation. In patients with malignant brain tumors, the loss of activity has been shown to be a promising predictor of response to alkylating agent-based chemotherapies, including BCNU (carmustine), CCNU and Temozolomide. The loss of MGMT activity in tumor cells can no longer repair the methyl adduct formation caused by the chemotherapy, leading to lethal cross-links between DNA strands. Most patients with methylated MGMT (m_MGMT) experience an increase in overall survival and time to progression of the disease. Source: Regenstrief LOINC

LP124510-1   gene methylation
DNA methylation is essential during embryonic development, and patterns of DNA methylation are generally transmitted to daughter cells with a high fidelity. In cancer, aberrant DNA methylation patterns are found in two distinct forms: hypermethylation and hypomethylation. Hypermethylation is one of the major epigenetic modifications that repress transcription via the promoter region of tumor suppressor genes. Hypermethylation typically occurs at CpG islands in the promoter region and is associated with gene inactivation. Hypomethylation, linked to chromosomal instability and loss of imprinting, arises earlier and occurs throughout the progression of cancer.

More specifically, methylated DNA can bind to methyl-CpG-binding domain proteins (MBDs), which recruit additional proteins such as histone deacetylases and other chromatin remodeling proteins that modify histones to form compact, inactive chromatin, termed silent chromatin. Loss of methyl-CpG-binding protein 2 (MeCP2) has been implicated in Rett syndrome; and methyl-CpG-binding domain protein 2 (MBD2) mediates the transcriptional silencing of hypermethylated genes in cancer. Research has suggested that long-term memory storage in humans may be regulated by DNA methylation. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, Wikipedia

Fully-Specified Name

Component

MGMT gene methylation

Property

Arb

Time

Pt

System

Tiss

Scale

Ord

Method

Molgen

Additional Names

Short Name

MGMT gene methylation Tiss Ql

Display Name

MGMT gene methylation Molgen Ql (Tiss)

Consumer Name Alpha Get Info

MGMT gene methylation, Tissue

Basic Attributes

Class

MOLPATH.MUT

Type

Laboratory

First Released

Version 2.34

Last Updated

Version 2.73

Order vs. Observation

Both

Common Test Rank Get Info

12760

Language Variants Get Info

Related Names

• Arbitrary
• DNA methylation
• Genetics
• Heredity
• Heritable
• Inherited
• Molecular genetics
• Molecular pathology
• MOLPATH
• MOLPATH.MUTATIONS
• Ordinal
• PCR
• Point in time
• QL
• Qual
• Qualitative
• Random
• Screen
• Tissue
• Tissue, unspecified

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=60252-4

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.